Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Articles|July 14, 2022

Amy Paller, MD, Discusses Long-Term Safety and Efficacy of Ixekizumab in Kids

Author(s)Miranda Hester

Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

ByMarie Bosslett, Assistant Editor

January 30th 2026

Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice

ByKaitlyn Bader, Assistant Managing Editor

January 20th 2026

Beyond the Plaques: How Psoriasis Shapes Work, Relationships, and Social Health

ByMaddi Hebebrand, MC, Associate Editor,Kaitlyn Bader, Assistant Managing Editor

January 17th 2026

Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib

ByMaddi Hebebrand, MC, Associate Editor,Graham Heap, MBBS, PhD

January 15th 2026

NPF Position Statement Aligns Severity Classification With Treatment Needs

ByMaddi Hebebrand, MC, Associate Editor

January 14th 2026

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Trending on Dermatology Times

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

Introducing Dermatology Times NP/PA Connect

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA